Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants.
WGS and Dante’s subsequent genomic reports are valuable health tools that can provide physicians and individuals with information on personalized dietary choices, predisposition to genetic diseases, genetic carrier information and more. Traditionally, DNA tests have been limited in the Baltic and Mediterranean regions due to costs and the availability of practitioners, services and resources. Longenesis will enrich its digital engagement platform by offering its network of participants discounted Dante offerings, including at-home, blood collection kits for WGS without the use of a needle, and additional women’s health reports without the need to re-test. This collaboration is hoped to encourage more people to pursue genomic solutions to help make personalised medicine more mainstream across Europe.
The Longenesis platform offers a digital, dynamic, secure engagement tool that empowers the public to explore and start using Dante’s novel genomic solutions. These digital tools will ensure legal and ethical compliances built into the Longenesis platform and offer streamlined consent for nearly 20,000 women around the world.
“Our new partnership with Dante Genomics will make it easier for women to access exciting new DNA testing opportunities that will provide greater health insights. Everyone deserves to have an individualized understanding of their health that DNA testing affords. We are excited to work with Dante Genomics to expand our European reach and positively impact more patients’ lives,” said Paolo Malerba, VP of Partnerships and Strategy at Longenesis.
“Personalized medicine needs personalized data, and it is collaborations like these that will allow us to offer genomic solutions to more people in more regions of the world,” said Andrea Riposati, CEO of Dante Genomics. “We are excited to partner with Longensis to increase access to these invaluable genomic solutions that can improve women’s health and ultimately save lives.”